Ulcerative colitis: Treatment updates

Jayashri G. Mahore; Nupur V. Deshpande; Rashmi V. Trivedi; Aniket S. Shelar

doi:10.5958/0974-360X.2020.00615.0

Research Journal of Pharmacy and Technology

ISSN

0974-360X (Online)
0974-3618 (Print)

Submit Article

Ulcerative colitis: Treatment updates

Author(s): Jayashri G. Mahore, Nupur V. Deshpande, Rashmi V. Trivedi, Aniket S. Shelar

Email(s): jayashri.mahore@dypvp.edu.in

DOI: 10.5958/0974-360X.2020.00615.0

Address: Jayashri G. Mahore1*, Nupur V. Deshpande1, Rashmi V. Trivedi2, Aniket S. Shelar1
1Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune - 411018, Maharashtra, India.
2SKB College of Pharmacy, New Kamptee, Nagpur.
*Corresponding Author

Published In: Volume - 13, Issue - 7, Year - 2020

View HTML

View PDF

ABSTRACT:
Ulcerative Colitis is a disease which produces inflammation of the colon. Ulcerative Colitis causes inflammation and open sores called ulcers in the lining of the colon and the rectum. Intestinal microbiota plays an important role in the cause and progression of the disease. Various treatment strategies have been developed till date for ulcerative colitis. Use of steroidal drug is treatment of choice. But incomplete recovery and recurrence after treatment is major drawback of steroidal treatment. Ayurvedic medicines also have been used as supportive line of treatment but it is not a choice of treatment because of slow recovery. Nowadays use of prebiotic is emerging which mainly acts by manipulating disturbed microbiota and considered as a sound strategy for treating ulcerative colitis. Researchers have studied the effect of different prebiotics on ulcerative colitis and results were very promising. In the present review various treatment aspects of ulcerative colitis have been reviewed.

Keywords:

Cite this article:
Jayashri G. Mahore, Nupur V. Deshpande, Rashmi V. Trivedi, Aniket S. Shelar. Ulcerative colitis: Treatment updates. Research J. Pharm. and Tech. 2020; 13(7): 3466-3471. doi: 10.5958/0974-360X.2020.00615.0

Cite(Electronic):
Jayashri G. Mahore, Nupur V. Deshpande, Rashmi V. Trivedi, Aniket S. Shelar. Ulcerative colitis: Treatment updates. Research J. Pharm. and Tech. 2020; 13(7): 3466-3471. doi: 10.5958/0974-360X.2020.00615.0 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-7-75

REFERENCES:

1. C.N. Bernstein, M. Fried, J.H. Krabshuis, H. Cohen, R. Eliakim, S. Fedail, R. Gearry, K.L. et al., Rey, A. Sood, F. Steinwurz, O.O. Thomsen, A. Thomsen G. Watermeyer. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010, Inflammatory bowel diseases 16(1) (2010) 112-24.

2. C. Cosnes, P. Gower-Rousseau, A. Seksik. Epidemiology and Natural History of Inflammatory Bowel Diseases, Gastroenterology 140(6) (2011) 1785-1794. e4.

3. M.A. Kamm. Review article: maintenance of remission in ulcerative colitis, Ailment. Pharmacol. Ther. 16 (Suppl. 4) (2002) 21-24.

4. B.C. Da Silva, A.C. Lyra, R. Rocha, G.O. Santana. Epidemiology, demographic characterestics and prognostic predictors of ulcerative colitis, World J. Gastroenterol. 20(2014) 948-9467.

5. D.C. Baumgart, W.J. Sandborn. Inflammatory bowel disease: clinical aspects and established and evolving therapies, The Lancet 369(9573) 1641-1657.

6. Cholapranee A, Ananthakrishnan AN. Environmental hygiene and risk inflammatory bowel diseases: A systematic review and meta-analysis. Inflammatory Bowel Disorder. 2016;22:2191-9.

7. De Souza HSP, Fiocchi C. Immunopathogenesis of IBD: Current state of the art. Nat Rev Gastroenterol Hepatol. 2016; 13:13-37.

8. Sasaki M, Klapproth JMA. The role of bacteria in the pathogenesis of ulcerative colitis. J Signal Transduct. 2012;2012, 704593.

9. Kyle Steenland, Subra Kugathasan, Dana Boyd Barr. PFOA and ulcerative colitis Environmental Research, Volume 165, August 2018, Pages 317-321.

10. Travis SP, Jewell DP. Ulcerative colitis: Clinical presentation and diagnosis. In: Satsangi J, Sutherland LR, editors. Inflammatory Bowel Diseases. London: Churchill Livingstone; 2003. P. 169-81.

11. Mao B, Li D, Zhao J, et al. In vitro fermentation of lactulose by human gut bacteria. J, Agric Food Chem. 2014;62:325-327.

12. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991–1030.

13. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:674–88.

14. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. The New England journal of medicine. 1994;330:1841-5.

15. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007;21:827–34.

16. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478–85.

17. Dick AP, Grayson MJ, Carpenter RG, Petrie A. A controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964;5:427-32.

18. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWF, Jones FA. An assessment of prednisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960;1:217-22.

19. Levi AJ, Fisher AM, Hughes L, Hendry WF. Male infertility due to sulphasalazine. Lancet 1979;2:276-8.

20. D’Inca R, Paccagnella M, Cardin R, et al. 5-ASA colonic mucosal concentrataions resulting from different pharmaceutical formulations in ulcerative colitis. World Journal Gastroenterol 2013 September 14;19(34):5665-70.

21. Bautzova, T., Rabiskova, M., Beduneau, A., Pellequer, Y. and Lamprecht, A., 2012. “Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis. Eur. J. Pharm. Biopharm. 81(2), 379-385.

22. Mihaela Friciu, M., Canh Le, T., Isoas-Szabo, P. and Mateescu, M. A., 2013. Carboxymethyl starch and lecithin complex as matrix for targeted drug delivery: I. Monolithic Mesalamine forms for colon delivery. Eur. J. Pharm. Biopharm. 85(3), 521-530.

23. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor-kB activation in mouse colonocytes. Gastroenterology 1999;116:602-609.

24. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-y. J Exp Med 2205;201:1205-1215.

25. Smith MA, Mohammad RA. Vedolizumab: an 47 integrin inhibitor for inflammatory bowel diseases. Ann Pharmacother. 2014;48:1629---35.

26. Haddley K. Vedolizumab for the treatment of inflammatory bowel disease. Drugs Today (Barc). 2014;50:309---19.

27. Cheifetz AS, Gianotti R, Luber R, et al. Complementary and alternative medicines used by patients with inflammatory bowel diseases. Gastroenterology 2017; 152:415-429.e15.

28. Ben-Arye E, Goldin E, Wengrower D et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002;37:444-449.

29. M. Nishio, K. Hirooka, Y. Doi, Chinese herbal drug natural indigo may cause pulmonary artery hypertension, Eur. Heart J. 37 (2016) 1992.

30. Kock NC. Construction of a continental ileostomy, Schweiz Med Wochenschr. 1971;101:729-734.

31. Jonkers D, Penders J, Masclee A, Pierik M. Prrobiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs, 2012;72:803-23.

32. Sekirov, I., Russell, S. L., Antunnes, L. C., & Finlay L. B. (2010). Gut microbiota in health and disease. Physiol Rev, 90, 859-904.

33. Wang Hongtao, Chen Cheng. Probiotics and their application. Agriculture products processing 2011;doi:10.3969/jissn.1671-9646©. 2011.03.003.

34. Siedner DL, Lashner BA, Brzezinski A et al. An oral supplement enriched with fish oil, soluble fiber and anti-oxidant for corticosteroid sparing in UC; a randomised, controlled trial and antioxidant for gastroenterol Hepatol. 2005; 3: 358-369.

35. Chen X, Zuo Q, Hai T, et al. Lactulose: an indirect antioxidant ametiorating inflammatory bowel disease by increasing hydrogen production. Med Hypotheses. 2011;76:325-327.